title: Erythropoietin on a tightrope: balancing neuronal and vascular protection between intrinsic and extrinsic pathways.
abstract: Enthusiasm for erythropoietin (EPO) as a broad cytoprotective agent continues to increase at an almost exponential rate. The premise that EPO was required only for erythropoiesis was eventually shed by recent work demonstrating the existence of EPO and its receptor in other organs and tissues outside of the liver and the kidney, such as the brain and heart. As a result, EPO has been identified as a possible candidate in the formulation of therapeutic strategies for both cardiac and nervous system diseases. EPO has been shown to mediate an array of vital cellular functions that involve progenitor stem cell development, cellular protection, angiogenesis, DNA repair, and cellular longevity. An important requirement to achieve the goal of preventing or even reducing cellular injury by any cytoprotective agent is the ability to uncover the cellular pathways that ultimately drive a cell to its demise. We present for consideration several critical cellular pathways modulated by EPO that involve Janus kinase 2 (Jak2), the serine-threonine kinase Akt, forkhead transcription factors, glycogen synthase kinase-3beta (GSK-3beta), cellular calcium, protein kinase C, caspases, as well as the control of inflammatory microglial activation. As we continue to gain new insight into these pathways, EPO should emerge as a critical agent for the development, maturation, and survival of cells throughout the body.
authors.affiliation: Division of Cellular and Molecular Cerebral Ischemia, Wayne State University School of Medicine, Detroit, Mich. 48201, USA.
authors.forename: Faqi
authors.initials: F
authors.lastname: Li
authors.forename: Zhao Zhong
authors.initials: ZZ
authors.lastname: Chong
authors.forename: Kenneth
authors.initials: K
authors.lastname: Maiese
mesh_terms: D000818:Animals; D004921:Erythropoietin / Q000502:physiology* / Q000627:therapeutic use*; D006801:Humans; D018696:Neuroprotective Agents / Q000494:pharmacology / Q000627:therapeutic use*; D015398:Signal Transduction / Q000187:drug effects / Q000502:physiology*; D014652:Vascular Diseases / Q000188:drug therapy / Q000378:metabolism*
chemical_list: D018696:Neuroprotective Agents; D004921:Erythropoietin